Astrana Health, Inc. (NASDAQ:ASTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Astrana Health, Inc. (NASDAQ:ASTH) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $63.67.

A number of research analysts recently commented on ASTH shares. Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. KeyCorp started coverage on shares of Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating for the company. Macquarie raised shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. Truist Financial cut their price target on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Finally, TD Cowen assumed coverage on Astrana Health in a research note on Monday, October 14th. They issued a “buy” rating and a $66.00 price objective on the stock.

Astrana Health Trading Up 2.0 %

Shares of ASTH stock opened at $36.99 on Wednesday. The firm has a market capitalization of $2.08 billion, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 1.42 and a beta of 1.20. Astrana Health has a 1 year low of $29.08 and a 1 year high of $63.20. The firm’s fifty day simple moving average is $36.04 and its 200 day simple moving average is $46.13. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same quarter in the prior year, the business earned $0.47 earnings per share. As a group, sell-side analysts predict that Astrana Health will post 1.15 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ASTH. State Street Corp acquired a new position in shares of Astrana Health during the third quarter worth approximately $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health in the 3rd quarter worth approximately $58,995,000. FMR LLC acquired a new position in Astrana Health during the 3rd quarter worth $48,413,000. SteelPeak Wealth LLC bought a new position in Astrana Health in the 3rd quarter valued at $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Astrana Health in the 3rd quarter valued at $30,251,000. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.